Dr. Michael M. Babich, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Boston University School of Medicine (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 164
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Boston University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
PA license MD062801L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Allegheny General Hospital Pittsburgh, PA
- Jefferson Hospital Jefferson Hills, PA
- West Penn Hospital Pittsburgh, PA
- Ahn Wexford Hospital Wexford, PA
- Canonsburg General Hospital Canonsburg, PA
Medical groups
- Allegheny Clinic (2,389 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 164
- Services billed
- 242
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 53 | 36 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 39 | 39 |
| Established patient office or other outpatient visit, 30-39 minutes | 37 | 32 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 30 | 30 |
| Established patient office or other outpatient visit, 20-29 minutes | 30 | 29 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 28 | 28 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 26 | 26 |
| Measurement of liver stiffness | 17 | 17 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | 16 |
| Biopsy of large bowel using a flexible endoscope | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Pittsburgh, PA | 150 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Pittsburgh, PA | 127 |
| Ursodiol Other prescribers in Pittsburgh, PA | 59 |
| Nadolol Other prescribers in Pittsburgh, PA | 31 |
| Furosemide Other prescribers in Pittsburgh, PA | 28 |
| Omeprazole Other prescribers in Pittsburgh, PA | 28 |
| Xifaxan (rifaximin) Other prescribers in Pittsburgh, PA | 27 |
| Spironolactone Other prescribers in Pittsburgh, PA | 20 |
| Gavilyte-C (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Pittsburgh, PA | 19 |
| Ocaliva (obeticholic acid) | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 53 payments worth $67,030 in total to this clinician.
| Ipsen Biopharmaceuticals, Inc | $37,703 |
|---|---|
| Madrigal Pharmaceuticals | $28,845 |
| Janssen Biotech, Inc. | $196 |
| Mallinckrodt Hospital Products Inc. | $145 |
| Phathom Pharmaceuticals, Inc. | $62.70 |
| Genzyme Corporation | $25.68 |
| AbbVie Inc. | $22.64 |
| Ardelyx, Inc. | $15.65 |
| Compensation for services other than consulting (speaking, faculty) | $62,268 |
|---|---|
| Travel and Lodging | $2,444 |
| Food and Beverage | $2,220 |
| Education | $99.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $9,604 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $5,288 |
| Madrigal Pharmaceuticals Jan 23, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,935 |
| Ipsen Biopharmaceuticals, Inc Jan 30, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Ipsen Biopharmaceuticals, Inc Feb 6, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Ipsen Biopharmaceuticals, Inc May 15, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Ipsen Biopharmaceuticals, Inc Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Ipsen Biopharmaceuticals, Inc Sep 23, 2025 | Compensation for services other than consulting (speaking, faculty) Bylvay · Gastroenterology | $4,312 |
| Ipsen Biopharmaceuticals, Inc Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Madrigal Pharmaceuticals Feb 4, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
All 21 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc Dec 9, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Ipsen Biopharmaceuticals, Inc Sep 23, 2025 | Compensation for services other than consulting (speaking, faculty) Bylvay · Gastroenterology | $4,312 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $5,288 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $472 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $256 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $244 |
| Janssen Biotech, Inc. Jun 9, 2025 | Education TREMFYA · Immunology · in-kind | $99.00 |
| Madrigal Pharmaceuticals Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Jun 5, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to TARENTUM, PA | $250 |
| Ipsen Biopharmaceuticals, Inc May 15, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Madrigal Pharmaceuticals Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Ipsen Biopharmaceuticals, Inc Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Madrigal Pharmaceuticals Mar 12, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $2,820 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $9,604 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $922 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $299 |
| Ipsen Biopharmaceuticals, Inc Feb 6, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Madrigal Pharmaceuticals Feb 4, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Ipsen Biopharmaceuticals, Inc Jan 30, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $4,312 |
| Madrigal Pharmaceuticals Jan 23, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,935 |
| Madrigal Pharmaceuticals Jan 17, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $2,115 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.